Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free PYRGF Stock Alerts

PyroGenesis Canada (PYRGF) Competitors

PyroGenesis Canada logo
$0.30 +0.01 (+1.80%)
As of 02:16 PM Eastern
Compare

PYRGF vs. NVCT, PLYX, ALXO, HRTX, and TENX

Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Nuvectis Pharma (NVCT), Polaryx Therapeutics (PLYX), ALX Oncology (ALXO), Heron Therapeutics (HRTX), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Nuvectis Pharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvectis PharmaN/A -143.91% -92.79%
PyroGenesis Canada -115.14%N/A -60.81%

PyroGenesis Canada has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvectis PharmaN/AN/A-$26.44M-$1.32N/A
PyroGenesis Canada$9.14M6.78-$21.12M-$0.05N/A

Nuvectis Pharma has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 3.09%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuvectis Pharma is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Nuvectis Pharma had 3 more articles in the media than PyroGenesis Canada. MarketBeat recorded 5 mentions for Nuvectis Pharma and 2 mentions for PyroGenesis Canada. Nuvectis Pharma's average media sentiment score of 0.03 beat PyroGenesis Canada's score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvectis Pharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

PyroGenesis Canada beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Polaryx Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
PyroGenesis Canada -115.14%N/A -60.81%

Polaryx Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 119.30%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

0.0% of PyroGenesis Canada shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Polaryx Therapeutics has higher earnings, but lower revenue than PyroGenesis Canada.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/AN/AN/AN/A
PyroGenesis Canada$9.14M6.78-$21.12M-$0.05N/A

In the previous week, PyroGenesis Canada had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for PyroGenesis Canada and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Polaryx Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Polaryx Therapeutics beats PyroGenesis Canada on 5 of the 9 factors compared between the two stocks.

How does PyroGenesis Canada compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

ALX Oncology has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat ALX Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
ALX OncologyN/A -182.01% -113.63%
PyroGenesis Canada -115.14%N/A -60.81%

ALX Oncology has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 136.87%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe ALX Oncology is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALX Oncology
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PyroGenesis Canada has higher revenue and earnings than ALX Oncology. PyroGenesis Canada is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/A-$101.69M-$1.90N/A
PyroGenesis Canada$9.14M6.78-$21.12M-$0.05N/A

In the previous week, ALX Oncology had 2 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.00 beat ALX Oncology's score of -0.26 indicating that PyroGenesis Canada is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALX Oncology
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

ALX Oncology beats PyroGenesis Canada on 8 of the 15 factors compared between the two stocks.

How does PyroGenesis Canada compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 5.9% of Heron Therapeutics shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Heron Therapeutics and Heron Therapeutics both had 2 articles in the media. Heron Therapeutics' average media sentiment score of 0.22 beat PyroGenesis Canada's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Heron Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Heron Therapeutics has a net margin of -13.04% compared to PyroGenesis Canada's net margin of -115.14%.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-13.04% N/A -4.62%
PyroGenesis Canada -115.14%N/A -60.81%

Heron Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 267.35%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Heron Therapeutics is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Heron Therapeutics has higher revenue and earnings than PyroGenesis Canada. Heron Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M1.49-$20.19M-$0.13N/A
PyroGenesis Canada$9.14M6.78-$21.12M-$0.05N/A

Summary

Heron Therapeutics beats PyroGenesis Canada on 10 of the 14 factors compared between the two stocks.

How does PyroGenesis Canada compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tenax Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Tenax Therapeutics and 2 mentions for PyroGenesis Canada. Tenax Therapeutics' average media sentiment score of 0.45 beat PyroGenesis Canada's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tenax Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PyroGenesis Canada
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tenax Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, PyroGenesis Canada has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Tenax Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -51.83% -49.51%
PyroGenesis Canada -115.14%N/A -60.81%

Tenax Therapeutics presently has a consensus price target of $29.67, suggesting a potential upside of 136.90%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tenax Therapeutics is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

PyroGenesis Canada has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.33N/A
PyroGenesis Canada$9.14M6.78-$21.12M-$0.05N/A

Summary

Tenax Therapeutics beats PyroGenesis Canada on 10 of the 16 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYRGF vs. The Competition

Export
MetricPyroGenesis CanadaPharmaceutical IndustryIndustrials SectorNASDAQ Exchange
Market Cap$61.98M$892.30M$9.35B$11.87B
Dividend YieldN/A4.84%3.57%5.21%
P/E Ratio-5.001.7225.1928.47
Price / Sales6.78120.124,989.6460.92
Price / CashN/A20.0727.0936.52
Price / Book-30.007.604.736.67
Net Income-$21.12M-$4.80M$792.42M$332.53M
7 Day Performance9.09%0.09%0.86%2.03%
1 Month Performance-22.78%5.64%7.14%9.23%
1 Year Performance-5.51%30.92%41.35%39.62%

PyroGenesis Canada Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYRGF
PyroGenesis Canada
N/A$0.30
+1.8%		N/AN/A$61.98M$9.14MN/A90
NVCT
Nuvectis Pharma
0.6059 of 5 stars		$8.54
-0.2%		$10.00
+17.1%		N/A$236.84MN/AN/A8
PLYX
Polaryx Therapeutics
N/A$4.88
-7.0%		$10.00
+104.9%		N/A$229.51MN/AN/A11
ALXO
ALX Oncology
3.4619 of 5 stars		$1.69
-0.6%		$4.60
+172.2%		N/A$228.75MN/AN/A40
HRTX
Heron Therapeutics
1.7167 of 5 stars		$1.27
+5.8%		$4.50
+254.3%		N/A$226.37M$154.90MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel